76 related articles for article (PubMed ID: 38660302)
1. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.
Pan B; Cheng J; Tan W; Wu X; Fan Q; Fan L; Jiang M; Yu R; Cheng X; Deng Y
Aging (Albany NY); 2024 May; 16(9):8171-8197. PubMed ID: 38738999
[TBL] [Abstract][Full Text] [Related]
2. PHLDA2 reshapes the immune microenvironment and induces drug resistance in hepatocellular carcinoma.
Feng K; Peng H; Lv Q; Zhang Y
Oncol Res; 2024; 32(6):1063-1078. PubMed ID: 38827322
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive prognostic and immunological analysis of Cullin2 in pan-cancer and its identification in hepatocellular carcinoma.
Jia L; Zhang X; Zhou T; Xie J; Jin J; Zhang D; Zhu C; Wan R
Aging (Albany NY); 2024 May; 16(10):8898-8921. PubMed ID: 38787355
[TBL] [Abstract][Full Text] [Related]
4. Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop.
Wang C; Ni J; Zhai D; Xu Y; Wu Z; Chen Y; Liu N; Du J; Shen Y; Liu G; Yang Y; You L; Hu W
Exp Mol Med; 2024 May; 56(5):1150-1163. PubMed ID: 38689092
[TBL] [Abstract][Full Text] [Related]
5. S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer.
Yang D; Zhao F; Zhou Y; Zhang Y; Shen J; Yu B; Zhao K; Ding Y
Int Immunopharmacol; 2024 Jun; 134():112076. PubMed ID: 38733818
[TBL] [Abstract][Full Text] [Related]
6. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory.
Chen J; Kaya NA; Zhang Y; Kendarsari RI; Sekar K; Lee Chong S; Seshachalam VP; Ling WH; Jin Phua CZ; Lai H; Yang H; Lu B; Lim JQ; Ma S; Chew SC; Chua KP; Alvarez JJS; Wu L; Ooi L; Chung AY; Cheow PC; Kam JH; Kow AW; Ganpathi IS; Bunchaliew C; Thammasiri J; Koh PS; Ong DB; Lim J; de Villa VH; Dela Cruz RD; Loh TJ; Wan WK; Leow WQ; Yang Y; Liu J; Skanderup AJ; Pang YH; Soon GST; Madhavan K; Lim TK; Bonney G; Goh BKP; Chew V; Dan YY; Toh HC; Foo RS; Tam WL; Zhai W; Chow PK
J Hepatol; 2024 May; ():. PubMed ID: 38782118
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
9. KHDRBS1 as a novel prognostic signaling biomarker influencing hepatocellular carcinoma cell proliferation, migration, immune microenvironment, and drug sensitivity.
Fan R; Liu F; Gong Q; Liu D; Tang S; Shen D
Front Immunol; 2024; 15():1393801. PubMed ID: 38660302
[TBL] [Abstract][Full Text] [Related]
10. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.
Zhang T; Wan C; Shi W; Xu J; Fan H; Zhang S; Lin Z; Ni R; Zhang X
J Mol Histol; 2015 Dec; 46(6):485-97. PubMed ID: 26438629
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis.
Zhao F; Liu A; Gong X; Chen H; Wei J; Chen B; Chen S; Yang R; Fan Y; Mao R
Tumori; 2022 Feb; 108(1):63-76. PubMed ID: 34165025
[TBL] [Abstract][Full Text] [Related]
13. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
14. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
15. Precision treatment in advanced hepatocellular carcinoma.
Yang X; Yang C; Zhang S; Geng H; Zhu AX; Bernards R; Qin W; Fan J; Wang C; Gao Q
Cancer Cell; 2024 Feb; 42(2):180-197. PubMed ID: 38350421
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
